-+ 0.00%
-+ 0.00%
-+ 0.00%

Family-Run Angelini Pharma Buys Catalyst Pharmaceuticals For Over 4 Billion

Benzinga·05/07/2026 15:45:57
Listen to the news

Shares of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) are trading higher on Thursday after Angelini Pharma agreed to acquire the company for $4.1 billion, or $31.50 per share.

The boards of Angelini Pharma and Catalyst unanimously approved the deal.

Angelini Group is a family-run company chaired by Thea Paola Angelini, a fourth-generation member of the Angelini family, led by Sergio Marullo di Condojanni, CEO of Angelini Pharma.

Catalyst is a biopharmaceutical company focused on rare diseases.

Catalyst Resolves Firdapse Patent Litigation

Separately, Catalyst announced that it has resolved the patent litigation it brought in response to an Abbreviated New Drug Application filed on behalf of Hetero USA Inc. seeking approval to market a generic version of Firdapse (amifampridine)10 mg tablets prior to expiration of the applicable Catalyst patents.

Firdapse is an FDA-approved prescription medication used to treat Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.

LEMS is a rare autoimmune disorder that affects the neuromuscular junction and causes muscle weakness.

CPRX Earnings Preview

The countdown is on: Catalyst Pharmaceuticals Inc. is set to report earnings on May 11, 2026 (confirmed).

  • EPS Estimate: 63 cents (Down from 68 cents)
  • Revenue Estimate: $147.96 million (Up from $141.42 million)
  • Valuation: P/E of 18.2x (Indicates fair valuation)

CPRX Stock Price Activity: Catalyst Pharmaceuticals shares were trading 2.06% higher at $31.15 at the time of publication on Thursday, according to Benzinga Pro data.

Photo: Shutterstock